Eiger Bio to Participate in September 2020 Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) announced participation in four investor conferences in September 2020. Highlights include:

• Panels at Citi's 15th Annual BioPharma Conference on September 9, discussing COVID-19 Therapeutics and Rare Disease Drug Development.
• A corporate update at the Baird Global Healthcare Conference on September 9.
• Participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16.
• A corporate update at the Cantor Global Virtual Healthcare Conference on September 17.

Live webcasts will be available on Eiger's website.

PALO ALTO, Calif., Sept. 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in four investor conferences in September:

• Citi's 15^th Annual BioPharma Conference.  Eiger will participate in two panels:
• "COVID-19 Therapeutics" on Wednesday, September 9, 9:50-10:20 AM ET
• "Challenges and Opportunities in Rare Disease Drug Development" on Wednesday, September 9, 4:15-4:45 PM ET
  
  
• Baird Global Healthcare Conference 2020.  Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET. 
  
  
• H.C. Wainwright 22^nd Annual Global Investment Conference from September 14- September 16.
  
  
• Cantor Global Virtual Healthcare Conference 2020.  Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET. 

Eiger will host one-on-one meetings at all conferences.  Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab.  A replay of the webcast will be available approximately one hour following the live event.

About Eiger
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist. 

Eiger's lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.  Eiger is developing two complementary treatments for HDV.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.  FDA PDUFA date is November 20, 2020.  

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Ingrid Choong, PhD
(650) 619-6115
ichoong@eigerbio.com  

Sri Ryali
(650) 272-6138
sryali@eigerbio.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-bio-to-participate-in-september-2020-investor-conferences-301121571.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What conferences will Eiger BioPharmaceuticals participate in September 2020?

Eiger will participate in four investor conferences, including Citi's 15th Annual BioPharma Conference, Baird Global Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, and Cantor Global Virtual Healthcare Conference.

When is the COVID-19 Therapeutics panel featuring Eiger?

The COVID-19 Therapeutics panel is scheduled for September 9, 2020, from 9:50 to 10:20 AM ET.

What is Eiger's lead clinical focus?

Eiger focuses on developing therapies for serious rare diseases, specifically targeting Hepatitis Delta Virus (HDV) infection.

What is the FDA PDUFA date for Eiger's lonafarnib NDA?

The FDA PDUFA date for Eiger's NDA for lonafarnib is November 20, 2020.

Where can I watch Eiger's conference presentations?

Live webcasts of Eiger's conference presentations will be available on their website under the 'Investors' tab.